14

Estrogen-Related Receptors and Breast Cancer: A Mini Review

Christina T. Teng[1] and Peggy R. Teng[2]
[1]*Division of National Toxicology Program, National Institute of Environmental Health Sciences, National Institutes of Health, Durham*
[2]*Department of Experimental Pathology and Laboratory Medicine, Anderson School of Management, UCLA Alumnus, Los Angeles*
United States of America

1. Introduction

The estrogen-related receptors (ERRs) α, β and γ comprise the NR3B orphan subgroup within the nuclear receptor superfamily. Although the ERRs were identified based on their sequence homology to estrogen receptor alpha (ERα), they do not bind estrogen or any other natural hormones. Recent studies have defined the roles of ERRs in the regulation of target genes at the transcriptional level as well as their participation in a broad range of physiological functions such as energy metabolism and growth progression. The expression of ERRs has been shown to be up-regulated in advanced breast cancer cells and is considered to be a negative prognostic marker for the diagnosis of the disease. This review will cover what is currently known in regards to the gene structure of ERRs in addition to their regulation, function and relationship to breast cancer.

Breast cancer is a complicated disease with 200,000 women diagnosed in the United States each year. There are many factors that influence breast cancer development and progression with hormone and nuclear receptors playing critical roles. Several reviews have been written on the emerging roles of estrogen and nuclear receptors in breast cancer (reviews (Conzen 2008; Hayashi, Niwa et al. 2009; Riggins, Mazzotta et al. 2010)). In this review we will focus on the estrogen-related receptor alpha, beta and gamma (ERRα, β and γ). ERRα and ERRβ were the first orphan nuclear receptors to be cloned in the late 1980's (Giguere, Yang et al. 1988) with ERRγ following 10 years later (Eudy, Yao et al. 1998; Hong, Yang et al. 1999; Heard, Norby et al. 2000). Although these receptors were cloned many years ago based on their sequence homology at the DNA binding domain to estrogen receptor alpha (ERα), their biological relevance (s) has only recently been uncovered (Giguere 2008; Villena and Kralli 2008) along with potential roles in cancer, and more specifically breast cancer.

1.1 Background of nuclear receptor family

ERRs belong to the orphan nuclear receptor NR3B subfamily which do not bind to any known natural ligands and are constitutively active in transcription (Benoit, Cooney et al. 2006). Crystal structure analyses of the ERRs revealed that the AF-2 containing helix 12,

essential for coactivator interaction (Nettles and Greene 2005), is in an active conformation while the ligand-binding pocket (LBP) remains empty (Greschik, Wurtz et al. 2002; Kallen, Schlaeppi et al. 2004). ERRs bind to TCAA/GGTCA elements called SFRE/ERRE and continually transactivate the target gene (Yang, Shigeta et al. 1996; Sladek, Beatty et al. 1997). While there are three members in this subfamily, both ERRβ (Zhou, Liu et al. 2006; Bombail, Collins et al. 2010) and ERRγ (Heard, Norby et al. 2000) have multiple variants that are expressed in a tissue-specific manner whereas there are no reports on variants of ERRα.

Although ERRs have high amino acid sequence homology, they are located on different chromosomes and cover a wide range of genomic space. The ESRRA gene is located at chromosome 11q13.1 (Shi, Shigeta et al. 1997) with a processed pseudogene present at 13q12.1 (Sladek, Beatty et al. 1997). It contains 7 exons and spans approximately 11 kbp genomic-space. The ESRRB gene is located at chromosome 14q24.3, has 12 exons and at least 5 variants from alternative splicing. It covers 130 kbp genomic-space ((Zhou, Liu et al. 2006; Collin, Kalay et al. 2008); Ensembl genome browser 61). The ESRRG gene spans 635 kbp genomic space, is located at chromosome 1q41 with 9 exons and 5 variants ((Eudy, Yao et al. 1998; Hong, Yang et al. 1999; Heard, Norby et al. 2000); Ensembl genome browser). A diagrammatic presentation of the relationship between ERRs and the ERs protein demonstrated that the highly conserved DNA binding domain (DBD) among the ERRs is closely related to the ERs DBD (Fig. 1). As indicated above, the ERR genes are located on different chromosomes which suggests that the gene and/or genome duplication event occurred over a long period of evolutionary time. Additionally, some of the coding exons are separated by large introns while others are clustered together.



Fig. 1. A. Protein structures of the ERRs and ERs. DBD, DNA binding domain; AF2, activation function 2. Number on top indicates the amino acid position of the modular domains for the nuclear receptor. % in the box indicates the amino acid sequence homology to ERRα within the same domain. B: Gene structures of the ERRs. The size of the gene and the locations of the exons (vertical bar or box) are in approximation. Chromosome locations and the approximate gene sizes are indicated.

1.2 Expression of ERRs

Surveying the expression of all 49 nuclear receptors from 39 mouse tissues uncovered the coordination of several nuclear receptor groups with the transcriptional programs necessary to affect distinct physiologic pathways (Bookout, Jeong et al. 2006). Indeed expression of some of the nuclear receptors including the ERRs is linked to the circadian clock in key metabolic tissues suggesting their role in regulation of nutrient and energy metabolism (Horard, Castet et al. 2004; Yang, Downes et al. 2006; Giguere 2008; Villena and Kralli 2008). These studies underscore the importance of regulation and expression of nuclear receptors in normal and abnormal physiological conditions. ERRα is ubiquitously expressed in all tissues examined and is especially abundant in those with high metabolic needs such as heart, skeletal muscle and kidney (Giguere 2008). In addition, ERRα is expressed in both human and mouse embryonic stem cells (Xie, Jeong et al. 2009), during adipocyte differentiation (Fu, Sun et al. 2005) and bone morphogenesis (Bonnelye and Aubin 2002; Bonnelye, Kung et al. 2002) suggesting its roles in differentiation and development. Although expression of ERRγ is more restricted and not detectable in every tissue examined with levels that are lower than ERRα, it is still highly expressed in metabolically active tissues such as brain, skeletal muscle, heart and kidney (Zhang and Teng 2007; Giguere 2008). It was thought that ERRβ was mainly expressed in embryo (Giguere, Yang et al. 1988; Luo, Sladek et al. 1997), however as detection methods improved, ERRβ expression was found to be present in eye, brain, thyroid, kidney and the heart of adult tissues (Bookout, Jeong et al. 2006). Although ERRβ is present at lower levels as compared to ERRα and ERRγ, it also exhibited a distinct diurnal rhythmic expression much like the other two in white fat (WAT), brown fat (BAT), liver and skeletal muscle. This suggests a potential role in the coordination of oxidative metabolism in these tissues (Yang, Downes et al. 2006). The expression of ERRs in these metabolically active tissues under circadian rhythm hints to potential overlapping functions in energy metabolism.

As stated earlier, the expression level of the receptors could be closely linked to their biological function in a cell-type specific manner. This is particularly relevant for a constitutive activator since they are not regulated by the addition of ligands. Therefore the function of ERRs could be controlled by their expression level; however information regarding the mechanisms and signals that regulate their expression is limited.

1.3 Regulation of ERRs

1.3.1 Estrogen regulation of ERRs

ERRα was demonstrated to be the target gene for estrogen in the mouse uterus (Shigeta, Zuo et al. 1997) 15 years ago. Later, a combinatorial estrogen response element which can bind several nuclear receptors termed multiple hormone response element (MHRE) was identified in the human ERRα gene promoter (Liu, Zhang et al. 2003). Under the influence of estrogen, the estrogen receptor alpha (ERα), (but not the estrogen receptor beta (ERβ)) was recruited to the chromatin of the human ERRα promoter which interacted with the MHRE in an indirect tethering manner and transactivated the promoter (Liu, Zhang et al. 2003; Hu, Kinyamu et al. 2008). Surprisingly, in a similar experiment conducted with ER negative SKBR3 cells, estrogen treatment also induced chromatin modification around the MHRE region and recruited the coregulators and RNA polymerase II to the ERRα promoter (Li, Birnbaumer et al. 2010). This suggests that the ERRα gene can be regulated by estrogen in a non-ER dependent manner. Indeed, the MHRE (a 57 bp region in human and a 34 bp region) in mouse of the ERRα gene is a pleiopropic response element for multiple nuclear receptors

(Liu, Zhang et al. 2005) and also serves as the binding site for ERRα and ERRγ (Laganiere, Tremblay et al. 2004; Mootha, Handschin et al. 2004; Liu, Zhang et al. 2005). ERRγ was recently found to be responsive to estrogen, its expression able to be stimulated in a dose dependent manner. Furthermore, this response can be blocked by the pure estrogen antagonist ICI 182,780 (Ijichi, Shigekawa et al. 2011). By using chromatin immunoprecipitation (ChIP)-on chip analysis with MCF-cells, a number of potential EREs in the second intron of the human ERRγ gene were previously identified (Carroll, Meyer et al. 2006). These studies demonstrated a functional cross-talk between ERs and ERRs in the estrogen signaling pathway.

1.3.2 PCG-1α regulation of ERRα

While nuclear receptor binding to its target gene is important for transcriptional activation, it requires specific interactions with coregulatory proteins (Glass, Rose et al. 1997; McKenna, Lanz et al. 1999). One of the key regulators in energy metabolism is peroxisome proliferator-activated receptor γ coactivator -1α (PGC-1α). PGC-1α not only interacts with and stimulates ERRα transcriptional activity, it also enhances its expression in an autoregulatory loop mechanism (Schreiber, Knutti et al. 2003; Laganiere, Tremblay et al. 2004; Mootha, Handschin et al. 2004; Zhang and Teng 2007; Wang, Li et al. 2008). By combining PGC-1α induced genome-wide transcriptional profiles with a computational strategy to detect cis-regulatory motifs approach, ERRα was discovered to be a key transcription factor that is involved in cross-talk with PGC-1α in regulating the oxidative phosphorylation pathway (Mootha, Handschin et al. 2004). PGC-1α is capable of co-activating nearly all known nuclear receptors and many other transcription factors (Puigserver and Spiegelman 2003), yet it possesses a unique protein interaction surface that is dedicated specifically to the ERRs (see review and references therein (Villena and Kralli 2008)). With this unique relationship, ERRα expression is co-regulated with PGC-1α under various physiological stimuli such as during fasting (Ichida, Nemoto et al. 2002), under cold exposure (Schreiber, Knutti et al. 2003) and exercise (Cartoni, Leger et al. 2005). Therefore, induction of PGC-1α expression by physiological stimuli also induces ERRα expression in a positive feed-forward mechanism. The expression level of ERRα is also affected by ERRγ (Liu, Zhang et al. 2005; Zhang and Teng 2007) and cAMP (Liu, Benlhabib et al. 2009). These studies showed that multiple mechanisms are involved in the regulation of ERRs expression and function.

1.4 Function of the ERRs

1.4.1 ERRs interactions with ERs and other nuclear receptors

Understanding the role of ERRs in ER-mediated function starts with their cloning. ERRα and ERRβ were identified based on a search for genes with sequence homology at the DNA binding domain to ERα (Giguere, Yang et al. 1988). Eight years later, ERRα was re-cloned as a specific binding protein to an extended hormone response element (HRE) half-site, the TCAAGGTCATC region of the human lactoferrin gene promoter (Yang, Shigeta et al. 1996). This finding revealed that ERRα binds to the steroidogenic factor 1 (SF-1) binding element termed SFRE and later renamed this element to ERRE as estrogen-related receptor response element whenever addressing the ERRs binding (Sladek, Bader et al. 1997). It was demonstrated that binding of ERRα to this ERRE enhances the ER-mediated estrogen response of the lactoferrin gene (Yang, Shigeta et al. 1996). ERRα was later shown to bind a variety of EREs as a monomer or homodimer (Johnston, Liu et al. 1997; Vanacker, Pettersson et al. 1999; Zhang and Teng 2000; Zhang and Teng 2001) and genes possessing such ERE or

ERRE or both were subject to ERRα regulation (Sladek, Beatty et al. 1997; Vega and Kelly 1997; Vanacker, Bonnelye et al. 1998; Vanacker, Delmarre et al. 1998; Sumi and Ignarro 2003). Other than the binding elements, ERRs and ERs recognize similar co-activators and co-repressors (Xie, Hong et al. 1999; Zhang and Teng 2000). Therefore, an extensive cross-talk between the ERRα and ERα occurs at the multiple steps of the transcriptional process ((Giguere 2002) and references therein). Depending on the EREs and the surrounding elements, ERRα could either enhance or inhibit the estrogen responsiveness of the target genes (Yang, Shigeta et al. 1996; Kraus, Ariazi et al. 2002; Zhang, Chen et al. 2006).
ERRβ represses glucocorticoid receptor (GR) activity (Trapp and Holsboer 1996) and inhibits the function of NF-E2 Related Factor 2 (Nrf2) on antioxidant response element mediated gene expression (Zhou, Lo et al. 2007) in a cell-specific manner. Recently, variant isoforms (Long and Short) of ERRβ were found in the human endometrium. Increasing the expression of the Long form enhanced the ERα-mediated stimulation of c-myc expression and cell proliferation in Ishikawa cells whereas the Short form had no effect (Bombail, Collins et al. 2010). Interestingly, ERRγ (but not ERRα or ERRβ) was shown to activate the orphan nuclear receptor small heterodimer partner (SHP; NR0B2) (Sanyal, Kim et al. 2002) and the dosage-sensitive sex reversal (DAX-1) promoter (Park, Ahn et al. 2005). ERRs could bind to the promoter of other nuclear receptors such as thyroid hormone receptor (TR) (Vanacker, Bonnelye et al. 1998; Castet, Herledan et al. 2006), PPARα (Huss, Torra et al. 2004), RXRα and RXRβ (Sonoda, Laganiere et al. 2007) thus potentially regulating their expression. These nuclear receptors are also involved in a wide range of physiological functions. Therefore, the cross-talk of ERRs with other nuclear receptors expands their functional roles and points to the importance of their expression in normal and diseased conditions.

1.4.2 The role of ERRs in homeostasis

A major advance in understanding the role of ERRα in energy homeostasis comes from the observation that the medium-chain acyl-coenzyme A dehydrogenase (MCAD) is an ERRα target (Sladek, Bader et al. 1997; Vega and Kelly 1997). The MCAD is an enzyme that mediates the first step in the mitochondrial β-oxidation of fatty acids (Schulz 1991). This was followed by the discovery of a close relationship between ERRα and PGC-1α in transcriptional regulation (Huss, Kopp et al. 2002; Ichida, Nemoto et al. 2002; Schreiber, Knutti et al. 2003). Evidence indicates that PGC-1α serves as a key regulator of mitochondrial biogenesis in mammals. This includes the activation of the transcription of mitochondrial uncoupling protein -1 (UCP-1) and the induction of the expression of NRF-1, NRF-2 and Tfam, all critical factors for mitochondrial function and maintenance. Furthermore, PGC-1α up-regulates the expression of genes involved in mitochondrial fatty acid oxidation and triggers mitochondrial proliferation (see review (Kelly and Scarpulla 2004)). The regulatory roles of PGC-1α in these key metabolic processes were mediated by ERRα (see review and references therein (Giguere 2008; Villena and Kralli 2008)). In microarray studies, over expression of PGC-1α in culture cells induced hundred of genes encoding mitochondrial proteins involved in fatty acid oxidation (FAO), the tricarboxylic acid cycle (TCA), oxidative phosphorylation (OXPHOS), mitochondrial membrane and carbohydrate metabolism. Interestingly, these PGC-1α effects can be blocked by siRNA against ERRα or be induced by over expression of constitutively active ERRα (Mootha, Handschin et al. 2004; Schreiber, Emter et al. 2004). Taken together, ERRα plays a major role

in the regulation of sets of genes involved in a wide range of energy balance activities such as lipid transport, fatty acid oxidation, TCA cycle, oxidative phosphorylation, and mitochondrial biogenesis to name a few.

2. ERRs in breast cancer

Searching for therapeutic targets in cancer biology is an important endeavor and the nuclear receptor has been shown to be one such target. Recently, the expression profile of 48 nuclear receptors in 51 human cancer cell lines derived from nine different tissues from the NC160 collection was investigated (Holbeck, Chang et al. 2010). The results uncovered a number of potential receptor-drug interactions and demonstrated that the individual receptor levels may predict a response to therapeutic intervention. Like all cancers, breast cancer is a complicated disease and many factors, estrogen in particular, contributes to its development and progression (Kelsey and Bernstein 1996). Although estrogen action is mediated through two receptors (ERα (Greene, Gilna et al. 1986) and ERβ (Kuiper, Enmark et al. 1996)), 70% of breast cancers express ERα which serves as the mediator for estrogen action (Russo, Hu et al. 2000; Conzen 2008; Hayashi, Niwa et al. 2009). In view of the structural similarity and functional cross-talk of the ERs and ERRs, it is possible that ERRs are also involved in breast cancer biology (review and references therein (Ariazi and Jordan 2006; Riggins, Mazzotta et al. 2010)).

2.1 ERRs as potential biomarkers

Using qPCR to measure the mRNA levels of ERs, epidermal growth factor receptor, ErbB family members, and ERR mRNA levels in 38 unselected primary breast tumors and 9 normal mammary gland epithelial cells from breast reduction surgery revealed that ERRα is highly expressed in a subset of tumors with elevated levels of ErbB2, an indicator of aggressive tumor behavior and nonfunctional ERα. Unlike ERRα, expression of ERRγ in breast tumors correlates with ER-positive status and ErbB4 expression which is a preferred clinical marker. These studies suggest that ERRα can be used as an unfavorable whereas ERRγ can serve as a favorable marker for diagnosis of clinical outcome. The mRNA level of ERRβ in the above mentioned breast tumor samples is very low and the potential as a biomarker unclear (Ariazi, Clark et al. 2002). Despite the proposed use of ERRγ as a favorable marker, over expression of ERRγ contributed to the development of tamoxifen (TAM)- resistance in cell lines derived from invasive lobular carcinoma (Riggins, Lan et al. 2008). Additional studies using an immunohistochemistry approach combined with RT-PCR supports the earlier findings that ERRα expression in breast carcinoma is associated with an increased risk of recurrence and an adverse clinical outcome (Suzuki, Miki et al. 2004).

2.2 ERRα and breast cancer cell growth

ERRα has been extensively studied in the context of breast cancer (Ariazi, Clark et al. 2002; Suzuki, Miki et al. 2004; Barry and Giguere 2005; Ariazi and Jordan 2006; Ariazi, Kraus et al. 2007; Stein, Chang et al. 2008; Chisamore, Wilkinson et al. 2009; Deblois, Hall et al. 2009; Stein, Gaillard et al. 2009; Dwyer, Joseph et al. 2010). Correlation between the expression of ERRs and disease outcome presents a first glimpse of the potential role of ERRs in breast cancer. Further studies using an unbiased microarray approach to understand the cross-talk between ERs and ERRs in MCF-7 cells yielded unexpected results (Stein, Chang et al. 2008). Despite the functional cross-talk between ERs and ERRs presented earlier, ERRα was found

to regulate a smaller set of genes that overlapped with ERα despite regulating many more genes not involved in estrogen signaling. Analysis of the microarray data from ER-regulated and ERR-regulated genes in MCF-7 cells by gene ontology (GO) showed that the majority of genes regulated by ERRα are involved in energy metabolism, oxidative stress and detoxification as expected. Interestingly, ERRα also induces vascular endothelial growth factor (VEGF), a highly angiogenic factor. Importantly, knockdown ERRα expression in MDA-MB-231 cells reduced tumor cell migration *in vitro* and tumor growth as xenografts *in vivo* (Stein, Chang et al. 2008). Further studies demonstrated that ERRα-dependent activation of VEGF mRNA expression occurs in several different breast cancer cell lines (Stein, Gaillard et al. 2009). This suggests that ERRα promotes tumor cell growth by stimulating VEGF expression. These studies together with the finding that ERRα also induces the pro-migratory factor, WNT11 (Dwyer, Joseph et al. 2010) provides a basis for highly expressed ERRα to be considered an overall negative phenotype of breast cancers.

2.3 ERRα and aromatase

As indicated above, there is much evidence that points to potential mechanisms of how ERRα influences breast cancer biology. ERRα plays a role in the local production of estrogen in breast cancer cells with levels in tumor tissue being several-fold higher than in normal circulating estrogen (Thorsen, Tangen et al. 1982; van Landeghem, Poortman et al. 1985) and aromatase, a key enzyme in converting androgens to estrogens, is also up-regulated in tumor cells (Miller and O'Neill 1987; Sasano and Harada 1998; Chen, Zhou et al. 1999). The presence of aromatase mRNA in the intra-tumoral location of 19 breast carcinoma tissues was detected using laser capture microdissection (LCM) and quantitative reverse transcription-PCR (q-PCR) while aromatase protein was verified by immunohistochemistry (Miki, Suzuki et al. 2007). Furthermore, microarray expression profiling of aromatase and ERRα mRNA in isolated carcinoma cells demonstrated a significant positive correlation (Miki, Suzuki et al. 2007). Although regulation of aromatase expression is tissue- and promoter-specific, its activity in breast carcinoma is higher than in normal tissue of the same patients (Silva, Rowlands et al. 1989; Miller, Anderson et al. 1990; Lipton, Santen et al. 1992). This suggests that the regulation of aromatase expression in breast cancer cells of the patient has been changed. Indeed, promoter switching in breast cancer tissue has been reported (Chen, Zhou et al. 1999; Chen, Reierstad et al. 2009) and ERRα plays a positive role (Yang, Zhou et al. 1998; Miao, Shi et al. 2010). Taken together, ERRα functions as a key modulator of intratumoral estrogen production in human breast carcinoma by stimulating the expression of the androgen-estrogen key converting enzyme, aromatase via tumor specific promoter usage.

2.4 ERRα and EGFR

ERRα has a close relationship with the ErbB2/epidermal growth factor receptor (EGFR) signaling pathway. ErbB2 is a receptor tyrosine kinase and in combination with EGFR, activates a complex array of downstream signaling pathways which leads to phosphorylation of multiple transcription factors including ERRα. Phosphorylation of these transcription factors promotes growth and proliferation (reviewed in ref. (Yarden and Sliwkowski 2001)). Upon EGF treatment, ERRα in MCF-7 cells was phosphorylated and preferentially recruited to the pS2 promoter. Furthermore, phosphorylated ERRα showed enhanced DNA binding capability in an *in vitro* study (Barry and Giguere 2005). Additionally, mitogen-activated protein kinases (MAPK) and Akts (components of the

ErbB2 pathway) are involved in ERRα phorphorylation and transactivation since inhibitors to MAPK and Akt also block ERRα target gene activation (Ariazi, Kraus et al. 2007). These observations suggest that ERRα phosphorylation provides a mechanism of enhanced transactivation function in breast cancer cells. Recently, using a mouse model of ErbB2-initiated mammary tumorigenesis found that ablation of ERRα significantly delays ErbB2-induced tumor development, lowers the levels of ErbB2 and co-amplifies transcripts within the 17q12-21 chromosomal region (the ErbB2 amplicon) (Deblois, Chahrour et al. 2010). The minimal 17q12 amplicon houses not only the ErbB2 gene; it also includes those involved in signal transduction, transcription, cell migration and invasion, inhibition of apotosis, genomic instability and tamoxifen resistance. ERRα binds to those genes and directs the recruitment of co-activators PGC-1β and RNA polymerase II to their promoters (Deblois, Chahrour et al. 2010). Furthermore, ERRα antagonists repress the effect of ERα on the ErbB2 promoter which leads to the development of tamoxifen resistance in breast cancer cells.

2.5 ERRα and AIB1

Comparing the co-activators along with the expression of various nuclear receptors in 48 primary breast tumor samples, a positive correlation between ERRα and AIB1 (amplified in breast cancer-1) (Anzick, Kononen et al. 1997) was found. AIB1 is an oncogenic co-activator of ERα that is frequently amplified and over expressed in human breast carcinomas (Anzick, Kononen et al. 1997; Liao, Kuang et al. 2002). In addition, these two proteins were abundant in the tumor samples and a direct interaction of the receptor and co-activator was demonstrated by fluorescence-resonance energy transfer, mammalian two-hybrid, and coimmunoprecipitation assay with endogenous proteins. On the other hand, the levels of PGC-1α (a well characterized ERRα co-activator) in primary breast carcinoma was low and no detectable association with ERRα was found (Heck, Rom et al. 2009). The enhanced association of ERRα with AIB1 underscores the functional significance of ERRα/AIB1 rather than the ERRα/PGC-1α interaction for breast tumor development and progression.

2.6 ERRγ and PGC-1β

Although direct evidence between cellular metabolism and breast cancer development is lacking, switching from aerobic oxidative phosphorylation to glycolytic metabolism is a typical feature of cancer cells (Warburg 1956). Recent reports demonstrated that the expression of miR-378, an ErbB2-regulated microRNA, correlates with the progression of human breast cancer by inducing the metabolic shift from an oxidative to a glycolytic pathway (Eichner, Perry et al. 2010). The miR-378 is embedded within PGC-1β and when expressed, inhibits the expression of ERRγ and GABPA (PGC-1β partners), a function that is opposite to the PGC-1 family of co-activators. In view of the close relationship of ERRs and PGC-1 coactivator family in the context of energy metabolism (Giguere 2008; Villena and Kralli 2008), the finding that miR-378 targets ERRγ but not ERRα demonstrated again that the isoforms of ERR possess differential functions as well as overlapping activities either in regulating energy or in breast cancer biology.

3. The potential agonist and antagonist of ERRs

As mentioned earlier, the ERR-coactivator or corepressor interaction determines the receptor's functional activity. Any factor that interrupts this interaction has the ability to modulate ERR function (Huss, Kopp et al. 2002; Kamei, Ohizumi et al. 2003; Schreiber, Knutti et al. 2003;

Debevec, Christian et al. 2007), therefore could be a potential therapeutic target site. Small-molecule agonists for ERRβ and ERRγ have been identified and characterized. However, identifying an agonist for ERRα has proved to be difficult (Yu and Forman 2005; Hyatt, Lockamy et al. 2007). Nonetheless, novel synthetic antagonists of ERRs, especially for ERRα, are emerging (Yang and Chen 1999; Coward, Lee et al. 2001; Tremblay, Bergeron et al. 2001; Tremblay, Kunath et al. 2001; Busch, Stevens et al. 2004; Willy, Murray et al. 2004; Chisamore, Cunningham et al. 2009). By disrupting the constitutive ERR/co-activator interaction or by inducing proteosome-dependent protein degradation of the receptor, these small molecules inhibit the function of ERRs and thus tumor growth and progression (Ariazi and Jordan 2006; Stein, Chang et al. 2008; Chisamore, Wilkinson et al. 2009; Heck, Rom et al. 2009; Wu, Wang et al. 2009). Recently, a series of diaryl ether-based ligands for ERRα were developed and demonstrated in animal models to be antidiabetic agents (Patch, Searle et al. 2011). Taken together, these studies provide a basis for the further development of therapeutics to treat breast cancers based on suppressing ERRα expression and activity. Recently, environmental estrogenic compounds were found to modulate ERRα (Suetsugi, Su et al. 2003) and ERRγ (Matsushima, Kakuta et al. 2007; Takashima-Sasaki, Mori et al. 2007; Wang, Fang et al. 2009; Hirvonen, Rajalin et al. 2011) activities in either a positive or negative manner. The impact of environmental factors on breast cancer via ERRs is currently unclear.

4. ERRs in other cancers

Since the over expression of ERRα in breast cancer was discovered (Ariazi, Clark et al. 2002; Suzuki, Miki et al. 2004), additional studies have found an association between the abnormal expression of ERRs and a variety of tumors and cancers such as prostate (Cheung, Yu et al. 2005; Yu, Wang et al. 2007; Yu, Wong et al. 2008), ovarian (Sun, Sehouli et al. 2005), colon-rectal (Cavallini, Notarnicola et al. 2005) and endometrium (Gao, Sun et al. 2006). In neoplastic prostatic tissues, ERRβ and ERRγ show levels that are either reduced or undetectable as compared to normal prostatic epithelial cells (Cheung, Yu et al. 2005). This suggests a down-regulation of these two receptors in prostate cancer. In a series of experiments, the forced induction of ERRβ or ERRγ in androgen sensitive (LNCaP) and androgen-insensitive (DU145) prostate cancer cells demonstrated that over expression of these two receptors suppresses cell proliferation and tumorigenicity of the cancer cells. The inhibition of prostate cancer cell proliferation was due to cell cycle arrest as demonstrated by the induction of cyclin-dependent kinase inhibitor p21 by ERRβ and p21/p27 by ERRγ. Moreover, ERRβ and ERRγ-mediated growth inhibition could be potentiated by their specific agonist DY131 and reduced by siRNA (Yu, Wang et al. 2007; Yu, Wong et al. 2008). The expression of ERRβ and ERRγ in prostate cancer is in contrast to ERRα in breast cancer cells, colorectal tumor, and malignant colon cells (Cavallini, Notarnicola et al. 2005). ERRα expression in endometrial adenocarcinoma is positively correlated with myometrial invasion while a negative correlation was observed between the expression of ERRγ mRNA and nodal metastasis (Gao, Sun et al. 2006). Therefore, the expression levels of the subtype ERRs in cancer cells provides a potential prognostic strategy for the therapeutic treatment of the cancer.

5. Conclusion

The studies cited in this review demonstrate that ERRs are differentially expressed in normal and cancer cells. While many factors influence their expression, ERRs in turn,

regulate many sets of genes involved in a wide variety of signaling pathways. As of today, the majority of studies are on ERRα and its relationship with breast cancer development and progression. How ERRα is involved in breast cancer biology is summarized in Figure 2.



Fig. 2. Potential pathways that regulate ERRα expression and influences breast cancer development and progression. Yellow arrow, upregulates ERRα expression; red arrow, downregulates ERRα activity; green arrow, potential mechanisms of ERRα action on breast cancer.

The roles of ERRγ in breast cancer have yet to be established. While ERRγ targets the same metabolic gene network as ERRα, it may perform distinct physiological functions such as participation in the metabolic shift pathway in breast cancer cells. ERRγ was recently demonstrated as a target for endocrine disruptors, the estrogen-mimic of the environmental chemicals which may be involved in breast cancer development or progression. Compared to ERRα and ERRγ, the number of functional studies on ERRβ has been relatively slim. Nonetheless, the report on the repressive function of ERRβ in prostate cancer cells will certainly garner additional attention to this orphan receptor. Collectively, the role of these ERRs in this disease state is emerging and they could prove to be a viable therapeutic target in the treatment of breast cancer.

6. References

Anzick, S. L., J. Kononen, et al. (1997). "AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer." *Science* 277(5328): 965-968.

Ariazi, E. A., G. M. Clark, et al. (2002). "Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer." *Cancer Res* 62(22): 6510-6518.

Ariazi, E. A. and V. C. Jordan (2006). "Estrogen-related receptors as emerging targets in cancer and metabolic disorders." *Curr Top Med Chem* 6(3): 203-215.

Ariazi, E. A., R. J. Kraus, et al. (2007). "Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway." *Mol Cancer Res* 5(1): 71-85.

Barry, J. B. and V. Giguere (2005). "Epidermal growth factor-induced signaling in breast cancer cells results in selective target gene activation by orphan nuclear receptor estrogen-related receptor alpha." *Cancer Res* 65(14): 6120-6129.

Benoit, G., A. Cooney, et al. (2006). "International Union of Pharmacology. LXVI. Orphan nuclear receptors." *Pharmacological reviews* 58(4): 798-836.

Bombail, V., F. Collins, et al. (2010). "Modulation of ER alpha transcriptional activity by the orphan nuclear receptor ERR beta and evidence for differential effects of long- and short-form splice variants." *Molecular and cellular endocrinology* 314(1): 53-61.

Bonnelye, E. and J. E. Aubin (2002). "Differential expression of estrogen receptor-related receptor alpha and estrogen receptors alpha and beta in osteoblasts in vivo and in vitro." *J Bone Miner Res* 17(8): 1392-1400.

Bonnelye, E., V. Kung, et al. (2002). "Estrogen receptor-related receptor alpha impinges on the estrogen axis in bone: potential function in osteoporosis." *Endocrinology* 143(9): 3658-3670.

Bookout, A. L., Y. Jeong, et al. (2006). "Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network." *Cell* 126(4): 789-799.

Busch, B. B., W. C. Stevens, Jr., et al. (2004). "Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha." *J Med Chem* 47(23): 5593-5596.

Carroll, J. S., C. A. Meyer, et al. (2006). "Genome-wide analysis of estrogen receptor binding sites." *Nat Genet* 38(11): 1289-1297.

Cartoni, R., B. Leger, et al. (2005). "Mitofusins 1/2 and ERR{alpha} expression are increased in human skeletal muscle after physical exercise." *J Physiol*.

Castet, A., A. Herledan, et al. (2006). "Receptor-interacting protein 140 differentially regulates estrogen receptor-related receptor transactivation depending on target genes." *Molecular Endocrinology* 20(5): 1035-1047.

Cavallini, A., M. Notarnicola, et al. (2005). "Oestrogen receptor-related receptor alpha (ERRalpha) and oestrogen receptors (ERalpha and ERbeta) exhibit different gene expression in human colorectal tumour progression." *Eur J Cancer* 41(10): 1487-1494.

Chen, D., S. Reierstad, et al. (2009). "Regulation of breast cancer-associated aromatase promoters." *Cancer Lett* 273(1): 15-27.

Chen, S., D. Zhou, et al. (1999). "Breast tumor aromatase: functional role and transcriptional regulation." *Endocr Relat Cancer* 6(2): 149-156.

Cheung, C. P., S. Yu, et al. (2005). "Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues." *J Clin Endocrinol Metab* 90(3): 1830-1844.

Chisamore, M. J., M. E. Cunningham, et al. (2009). "Characterization of a novel small molecule subtype specific estrogen-related receptor alpha antagonist in MCF-7 breast cancer cells." *PLoS One* 4(5): e5624.

Chisamore, M. J., H. A. Wilkinson, et al. (2009). "Estrogen-related receptor-alpha antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts." *Mol Cancer Ther* 8(3): 672-681.

Collin, R. W., E. Kalay, et al. (2008). "Mutations of ESRRB encoding estrogen-related receptor beta cause autosomal-recessive nonsyndromic hearing impairment DFNB35." *American journal of human genetics* 82(1): 125-138.

Conzen, S. D. (2008). "Minireview: nuclear receptors and breast cancer." *Mol Endocrinol* 22(10): 2215-2228.

Coward, P., D. Lee, et al. (2001). "4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma." *Proc Natl Acad Sci U S A* 98(15): 8880-8884.

Debevec, D., M. Christian, et al. (2007). "Receptor interacting protein 140 regulates expression of uncoupling protein 1 in adipocytes through specific peroxisome proliferator activated receptor isoforms and estrogen-related receptor alpha." *Mol Endocrinol* 21(7): 1581-1592.

Deblois, G., G. Chahrour, et al. (2010). "Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis." *Cancer Res* 70(24): 10277-10287.

Deblois, G., J. A. Hall, et al. (2009). "Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity." *Cancer Res* 69(15): 6149-6157.

Dwyer, M. A., J. D. Joseph, et al. (2010). "WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration." *Cancer Res* 70(22): 9298-9308.

Eichner, L. J., M. C. Perry, et al. (2010). "miR-378(*) mediates metabolic shift in breast cancer cells via the PGC-1beta/ERRgamma transcriptional pathway." *Cell Metab* 12(4): 352-361.

Eudy, J. D., S. Yao, et al. (1998). "Isolation of a gene encoding a novel member of the nuclear receptor superfamily from the critical region of Usher syndrome type IIa at 1q41." *Genomics* 50(3): 382-384.

Fu, M., T. Sun, et al. (2005). "A Nuclear Receptor Atlas: 3T3-L1 adipogenesis." *Molecular Endocrinology* 19(10): 2437-2450.

Gao, M., P. Sun, et al. (2006). "Expression of estrogen receptor-related receptor isoforms and clinical significance in endometrial adenocarcinoma." *Int J Gynecol Cancer* 16(2): 827-833.

Giguere, V. (2002). "To ERR in the estrogen pathway." *Trends Endocrinol Metab* 13(5): 220-225.

Giguere, V. (2008). "Transcriptional control of energy homeostasis by the estrogen-related receptors." *Endocr Rev* 29(6): 677-696.

Giguere, V., N. Yang, et al. (1988). "Identification of a new class of steroid hormone receptors." *Nature* 331: 91-94.

Glass, C. K., D. W. Rose, et al. (1997). "Nuclear receptor coactivators." *Current opinion in cell biology* 9(2): 222-232.

Greene, G. L., P. Gilna, et al. (1986). "Sequence and expression of human estrogen receptor complementary DNA." *Science* 231(4742): 1150-1154.

Greschik, H., J. M. Wurtz, et al. (2002). "Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3." *Mol Cell* 9(2): 303-313.

Hayashi, S., T. Niwa, et al. (2009). "Estrogen signaling pathway and its imaging in human breast cancer." *Cancer Sci* 100(10): 1773-1778.

Heard, D. J., P. L. Norby, et al. (2000). "Human ERR gamma, a third member of the estrogen receptor- related receptor (ERR) subfamily of orphan nuclear receptors: Tissue-specific isoforms are expressed during development and in the adult." *Molecular Endocrinology* 14(3): 382-392.

Heck, S., J. Rom, et al. (2009). "Estrogen-related receptor alpha expression and function is associated with the transcriptional coregulator AIB1 in breast carcinoma." *Cancer Res* 69(12): 5186-5193.

Hirvonen, J., A.-M. Rajalin, et al. (2011). "Transcriptional activity of estrogen-related receptor [gamma] (ERR[gamma]) is stimulated by the phytoestrogen equol." *The Journal of Steroid Biochemistry and Molecular Biology* 123(1-2): 46-57.

Holbeck, S., J. Chang, et al. (2010). "Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions." *Mol Endocrinol* 24(6): 1287-1296.

Hong, H., L. Yang, et al. (1999). "Hormone-independent transcriptional activation and coactivator binding by novel orphan nuclear receptor ERR3." *J Biol Chem* 274(32): 22618-22626.

Horard, B., A. Castet, et al. (2004). "Dimerization is required for transactivation by estrogen-receptor-related (ERR) orphan receptors: evidence from amphioxus ERR." *J Mol Endocrinol* 33(2): 493-509.

Hu, P., H. K. Kinyamu, et al. (2008). "Estrogen induces estrogen-related receptor alpha gene expression and chromatin structural changes in estrogen receptor (ER)-positive and ER-negative breast cancer cells." *J Biol Chem* 283(11): 6752-6763.

Huss, J. M., R. P. Kopp, et al. (2002). "Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identification of novel leucine-rich interaction motif within PGC-1alpha." *J Biol Chem* 277(43): 40265-40274.

Huss, J. M., I. P. Torra, et al. (2004). "Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle." *Mol Cell Biol* 24(20): 9079-9091.

Hyatt, S. M., E. L. Lockamy, et al. (2007). "On the intractability of estrogen-related receptor alpha as a target for activation by small molecules." *J Med Chem* 50(26): 6722-6724.

Ichida, M., S. Nemoto, et al. (2002). "Identification of a specific molecular repressor of the peroxisome proliferator-activated receptor gamma Coactivator-1 alpha (PGC-1alpha)." *J Biol Chem* 277(52): 50991-50995.

Ijichi, N., T. Shigekawa, et al. (2011). "Estrogen-related receptor gamma modulates cell proliferation and estrogen signaling in breast cancer." *J Steroid Biochem Mol Biol* 123(1-2): 1-7.

Johnston, S. D., X. Liu, et al. (1997). "Estrogen-related receptor alpha 1 functionally binds as a monomer to extended half-site sequences including ones contained within estrogen- response elements." *Mol Endocrinol* 11(3): 342-352.

Kallen, J., J. M. Schlaeppi, et al. (2004). "Evidence for Ligand-independent Transcriptional Activation of the Human Estrogen-related Receptor {alpha} (ERR{alpha}): CRYSTAL STRUCTURE OF ERR{alpha} LIGAND BINDING DOMAIN IN

COMPLEX WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR COACTIVATOR-1{alpha}." *J Biol Chem* 279(47): 49330-49337.

Kamei, Y., H. Ohizumi, et al. (2003). "PPARgamma coactivator 1beta/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity." *Proc Natl Acad Sci U S A* 100(21): 12378-12383.

Kelly, D. P. and R. C. Scarpulla (2004). "Transcriptional regulatory circuits controlling mitochondrial biogenesis and function." *Genes & development* 18(4): 357-368.

Kelsey, J. L. and L. Bernstein (1996). "Epidemiology and prevention of breast cancer." *Annu Rev Public Health* 17: 47-67.

Kraus, R. J., E. A. Ariazi, et al. (2002). "Estrogen-related receptor alpha 1 actively antagonizes estrogen receptor-regulated transcription in MCF-7 mammary cells." *J Biol Chem* 277(27): 24826-24834.

Kuiper, G. G., E. Enmark, et al. (1996). "Cloning of a novel receptor expressed in rat prostate and ovary." *Proc Natl Acad Sci U S A* 93(12): 5925-5930.

Laganiere, J., G. B. Tremblay, et al. (2004). "A Polymorphic Autoregulatory Hormone Response Element in the Human Estrogen-related Receptor {alpha} (ERR{alpha}) Promoter Dictates Peroxisome Proliferator-activated Receptor {gamma} Coactivator-1{alpha} Control of ERR{alpha} Expression." *J Biol Chem* 279(18): 18504-18510.

Li, Y., L. Birnbaumer, et al. (2010). "Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1." *Molecular Endocrinology* 24(5): 969-980.

Liao, L., S. Q. Kuang, et al. (2002). "Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1." *J Steroid Biochem Mol Biol* 83(1-5): 3-14.

Lipton, A., R. J. Santen, et al. (1992). "Prognostic value of breast cancer aromatase." *Cancer* 70(7): 1951-1955.

Liu, D., H. Benlhabib, et al. (2009). "cAMP Enhances estrogen-related receptor {alpha} (ERR{alpha}) transcriptional activity at the SP-A promoter by increasing its interaction with protein kinase A and steroid receptor coactivator 2 (SRC-2)." *Mol Endocrinol* 23(6): 772-783.

Liu, D., Z. Zhang, et al. (2003). "Estrogen Stimulates Estrogen-Related Receptor {alpha} Gene Expression Through Conserved Hormone Response Elements." *Endocrinology* 144(11): 4894-4904.

Liu, D., Z. Zhang, et al. (2005). "Estrogen-related receptor-gamma and peroxisome proliferator-activated receptor-gamma coactivator-1alpha regulate estrogen-related receptor-alpha gene expression via a conserved multi-hormone response element." *J Mol Endocrinol* 34(2): 473-487.

Luo, J., R. Sladek, et al. (1997). "Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-beta." *Nature* 388(6644): 778-782.

Matsushima, A., Y. Kakuta, et al. (2007). "Structural evidence for endocrine disruptor bisphenol A binding to human nuclear receptor ERR gamma." *J Biochem* 142(4): 517-524.

McKenna, N. J., R. B. Lanz, et al. (1999). "Nuclear receptor coregulators: cellular and molecular biology." *Endocrine reviews* 20(3): 321-344.

Miao, L., J. Shi, et al. (2010). "Estrogen receptor-related receptor alpha mediates up-regulation of aromatase expression by prostaglandin E2 in prostate stromal cells." *Mol Endocrinol* 24(6): 1175-1186.

Miki, Y., T. Suzuki, et al. (2007). "Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells." *Cancer Res* 67(8): 3945-3954.

Miller, W. R., T. J. Anderson, et al. (1990). "Relationship between tumour aromatase activity, tumour characteristics and response to therapy." *J Steroid Biochem Mol Biol* 37(6): 1055-1059.

Miller, W. R. and J. O'Neill (1987). "The importance of local synthesis of estrogen within the breast." *Steroids* 50(4-6): 537-548.

Mootha, V. K., C. Handschin, et al. (2004). "Err{alpha} and Gabpa/b specify PGC-1{alpha}-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle." *Proc Natl Acad Sci U S A*.

Nettles, K. W. and G. L. Greene (2005). "Ligand control of coregulator recruitment to nuclear receptors." *Annual review of physiology* 67: 309-333.

Park, Y. Y., S. W. Ahn, et al. (2005). "An autoregulatory loop controlling orphan nuclear receptor DAX-1 gene expression by orphan nuclear receptor ERRgamma." *Nucleic acids research* 33(21): 6756-6768.

Patch, R. J., L. L. Searle, et al. (2011). "Identification of Diaryl Ether-Based Ligands for Estrogen-Related Receptor alpha as Potential Antidiabetic Agents." *J Med Chem*.

Puigserver, P. and B. M. Spiegelman (2003). "Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator." *Endocr Rev* 24(1): 78-90.

Riggins, R. B., J. P. Lan, et al. (2008). "ERR{gamma} Mediates Tamoxifen Resistance in Novel Models of Invasive Lobular Breast Cancer." *Cancer Res* 68(21): 8908-8917.

Riggins, R. B., M. M. Mazzotta, et al. (2010). "Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response." *Endocr Relat Cancer* 17(3): R213-231.

Russo, J., Y. F. Hu, et al. (2000). "Developmental, cellular, and molecular basis of human breast cancer." *J Natl Cancer Inst Monogr*(27): 17-37.

Sanyal, S., J. Y. Kim, et al. (2002). "Differential regulation of the orphan nuclear receptor small heterodimer partner (SHP) gene promoter by orphan nuclear receptor ERR isoforms." *The Journal of biological chemistry* 277(3): 1739-1748.

Sasano, H. and N. Harada (1998). "Intratumoral aromatase in human breast, endometrial, and ovarian malignancies." *Endocr Rev* 19(5): 593-607.

Schreiber, S. N., R. Emter, et al. (2004). "The estrogen-related receptor {alpha} (ERR{alpha}) functions in PPAR{gamma} coactivator 1{alpha} (PGC-1{alpha})-induced mitochondrial biogenesis." *Proc Natl Acad Sci U S A*.

Schreiber, S. N., D. Knutti, et al. (2003). "The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor ERRalpha." *J Biol Chem*.

Schulz, H. (1991). "Beta oxidation of fatty acids." *Biochimica et biophysica acta* 1081(2): 109-120.

Shi, H., H. Shigeta, et al. (1997). "Human estrogen receptor-like 1 (ESRL1) gene: genomic organization, chromosomal localization, and promoter characterization." *Genomics* 44(1): 52-60.

Shigeta, H., W. Zuo, et al. (1997). "The mouse estrogen receptor-related orphan receptor alpha 1: molecular cloning and estrogen responsiveness." *J Mol Endocrinol* 19(3): 299-309.

Silva, M. C., M. G. Rowlands, et al. (1989). "Intratumoral aromatase as a prognostic factor in human breast carcinoma." *Cancer Res* 49(10): 2588-2591.

Sladek, R., J. A. Bader, et al. (1997). "The orphan nuclear receptor estrogen-related receptor alpha is a transcriptional regulator of the human medium-chain acyl coenzyme A dehydrogenase gene." *Mol Cell Biol* 17(9): 5400-5409.

Sladek, R., B. Beatty, et al. (1997). "Chromosomal mapping of the human and murine orphan receptors ERR alpha (ESRRA) and ERR beta (ESRRB) and identification of a novel human ERR alpha-related pseudogene." *Genomics* 45(2): 320-326.

Sonoda, J., J. Laganiere, et al. (2007). "Nuclear receptor ERR alpha and coactivator PGC-1 beta are effectors of IFN-gamma-induced host defense." *Genes & development* 21(15): 1909-1920.

Stein, R. A., C. Y. Chang, et al. (2008). "Estrogen-Related Receptor {alpha} Is Critical for the Growth of Estrogen Receptor-Negative Breast Cancer." *Cancer Res* 68(21): 8805-8812.

Stein, R. A., S. Gaillard, et al. (2009). "Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells." *J Steroid Biochem Mol Biol* 114(1-2): 106-112.

Suetsugi, M., L. Su, et al. (2003). "Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors." *Mol Cancer Res* 1(13): 981-991.

Sumi, D. and L. J. Ignarro (2003). "Estrogen-related receptor {alpha}1 up-regulates endothelial nitric oxide synthase expression." *Proc Natl Acad Sci U S A* 100(24): 14451-14456.

Sun, P., J. Sehouli, et al. (2005). "Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells." *J Mol Med* 83(6): 457-467.

Suzuki, T., Y. Miki, et al. (2004). "Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor." *Cancer Res* 64(13): 4670-4676.

Takashima-Sasaki, K., C. Mori, et al. (2007). "Exposure of juvenile female mice to isoflavone causes lowered expression of estrogen-related receptor gamma gene in vagina." *Reprod Toxicol* 23(4): 507-512.

Thorsen, T., M. Tangen, et al. (1982). "Concentration of endogenous oestradiol as related to oestradiol receptor sites in breast tumor cytosol." *Eur J Cancer Clin Oncol* 18(4): 333-337.

Trapp, T. and F. Holsboer (1996). "Nuclear orphan receptor as a repressor of glucocorticoid receptor transcriptional activity." *The Journal of biological chemistry* 271(17): 9879-9882.

Tremblay, G. B., D. Bergeron, et al. (2001). "4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear receptors beta and gamma." *Endocrinology* 142(10): 4572-4575.

Tremblay, G. B., T. Kunath, et al. (2001). "Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta." *Genes Dev* 15(7): 833-838.

van Landeghem, A. A., J. Poortman, et al. (1985). "Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue." *Cancer Res* 45(6): 2900-2906.

Vanacker, J. M., E. Bonnelye, et al. (1998). "Activation of the thyroid hormone receptor alpha gene promoter by the orphan nuclear receptor ERR alpha." *Oncogene* 17(19): 2429-2435.

Vanacker, J. M., C. Delmarre, et al. (1998). "Activation of the osteopontin promoter by the orphan nuclear receptor estrogen receptor related alpha." *Cell Growth Differ* 9(12): 1007-1014.

Vanacker, J. M., K. Pettersson, et al. (1999). "Transcriptional targets shared by estrogen receptor- related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta." *Embo J* 18(15): 4270-4279.

Vega, R. B. and D. P. Kelly (1997). "A role for estrogen-related receptor alpha in the control of mitochondrial fatty acid beta-oxidation during brown adipocyte differentiation." *J Biol Chem* 272(50): 31693-31699.

Villena, J. A. and A. Kralli (2008). "ERRalpha: a metabolic function for the oldest orphan." *Trends Endocrinol Metab* 19(8): 269-276.

Wang, J., F. Fang, et al. (2009). "Kaempferol is an estrogen-related receptor alpha and gamma inverse agonist." *FEBS Lett* 583(4): 643-647.

Wang, L., Y. Li, et al. (2008). "PGC-1 alpha induces dynamic protein interactions on the ERR alpha gene multi-hormone response element nucleosome in kidney cells." *Biochem J* 416: 407-419.

Warburg, O. (1956). "On respiratory impairment in cancer cells." *Science* 124(3215): 269-270.

Willy, P. J., I. R. Murray, et al. (2004). "Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand." *Proc Natl Acad Sci U S A* 101(24): 8912-8917.

Wu, F., J. Wang, et al. (2009). "Estrogen-related receptor alpha (ERRalpha) inverse agonist XCT-790 induces cell death in chemotherapeutic resistant cancer cells." *Chem Biol Interact* 181(2): 236-242.

Xie, C. Q., Y. Jeong, et al. (2009). "Expression profiling of nuclear receptors in human and mouse embryonic stem cells." *Molecular Endocrinology* 23(5): 724-733.

Xie, W., H. Hong, et al. (1999). "Constitutive activation of transcription and binding of coactivator by estrogen-related receptors 1 and 2." *Mol Endocrinol* 13(12): 2151-2162.

Yang, C. and S. Chen (1999). "Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor." *Cancer Res* 59(18): 4519-4524.

Yang, C., D. Zhou, et al. (1998). "Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor." *Cancer Res* 58(24): 5695-5700.

Yang, N., H. Shigeta, et al. (1996). "Estrogen-related receptor, hERR1, modulates estrogen receptor-mediated response of human lactoferrin gene promoter." *J Biol Chem* 271(10): 5795-5804.

Yang, X., M. Downes, et al. (2006). "Nuclear receptor expression links the circadian clock to metabolism." *Cell* 126(4): 801-810.

Yarden, Y. and M. X. Sliwkowski (2001). "Untangling the ErbB signalling network." *Nat Rev Mol Cell Biol* 2(2): 127-137.

Yu, D. D. and B. M. Forman (2005). "Identification of an agonist ligand for estrogen-related receptors ERRbeta/gamma." *Bioorg Med Chem Lett* 15(5): 1311-1313.

Yu, S., X. Wang, et al. (2007). "ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer." *Cancer Res* 67(10): 4904-4914.

Yu, S., Y. C. Wong, et al. (2008). "Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer." *Oncogene* 27(23): 3313-3328.

Zhang, Z., K. Chen, et al. (2006). "Estrogen-related receptors-stimulated monoamine oxidase B promoter activity is down-regulated by estrogen receptors." *Mol Endocrinol* 20(7): 1547-1561.

Zhang, Z. and C. T. Teng (2000). "Estrogen receptor-related receptor alpha 1 interacts with coactivator and constitutively activates the estrogen response elements of the human lactoferrin gene." *J Biol Chem* 275(27): 20837-20846.

Zhang, Z. and C. T. Teng (2001). "Estrogen receptor alpha and estrogen receptor-related receptor alpha1 compete for binding and coactivator." *Mol Cell Endocrinol* 172(1-2): 223-233.

Zhang, Z. and C. T. Teng (2007). "Interplay between estrogen-related receptor alpha (ERRalpha) and gamma (ERRgamma) on the regulation of ERRalpha gene expression." *Mol Cell Endocrinol* 264(1-2): 128-141.

Zhou, W., Z. Liu, et al. (2006). "Identification and characterization of two novel splicing isoforms of human estrogen-related receptor beta." *The Journal of clinical endocrinology and metabolism* 91(2): 569-579.

Zhou, W., S. C. Lo, et al. (2007). "ERRbeta: a potent inhibitor of Nrf2 transcriptional activity." *Molecular and cellular endocrinology* 278(1-2): 52-62.



Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways

Edited by Prof. Mehmet Gunduz

ISBN 978-953-307-714-7
Hard cover, 732 pages
Publisher InTech
Published online 30, November, 2011
Published in print edition November, 2011

Cancer is the leading cause of death in most countries and its consequences result in huge economic, social and psychological burden. Breast cancer is the most frequently diagnosed cancer type and the leading cause of cancer death among females. In this book, we discussed various aspects of breast cancer carcinogenesis from clinics to its hormone-based as well as genetic-based etiologies for this deadly cancer. We hope that this book will contribute to the development of novel diagnostic as well as therapeutic approaches.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Christina T. Teng and Peggy R. Teng (2011). Estrogen-Related Receptors and Breast Cancer: A Mini Review, Breast Cancer - Carcinogenesis, Cell Growth and Signalling Pathways, Prof. Mehmet Gunduz (Ed.), ISBN: 978-953-307-714-7, InTech, Available from: http://www.intechopen.com/books/breast-cancer-carcinogenesis-cell-growth-and-signalling-pathways/estrogen-related-receptors-and-breast-cancer-a-mini-review

INTECH
open science | open minds

InTech Europe
University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

IntechOpen